Biotech | October 04, 2022
The combination of Optym, Emmes' ophthalmology certification unit, and Clinical Edge will make the organization a leader in ophthalmic certification and training services
Dr. Bunker will focus on leading Research and Development (R&D) in San Diego, advancing the preclinical pipeline and optimizing the Company’s Integrated Discovery Engine.
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
The company has partnered with Neethi, a Kerala state cooperative consumers federation limited company, to run this program in Kerala
They also noted ProBioGen's digitalization investments and strategy, as well as its support for its employees.
He takes over leadership of Cell & Gene from Jean-Christophe Hyvert, enabling Jean-Christophe to increase his focus on his role as President of the Biologics Division
Investment further strengthens Merck's "Big 3," the key drivers for increasing Group sales to approximately € 25 billion by 2025
Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases.
Subscribe To Our Newsletter & Stay Updated
